Compass Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations (Unaudited)
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
(In thousands, except per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Licensing revenue | $— | $— | $850 | $— |
| Operating expenses: | ||||
| Research and development | 8,612 | 8,831 | 29,304 | 25,694 |
| General and administrative | 3,627 | 3,095 | 11,597 | 9,276 |
| Total operating expenses | 12,239 | 11,926 | 40,901 | 34,970 |
| Loss from operations | (12,239) | (11,926) | (40,051) | (34,970) |
| Other income | 1,758 | 1,962 | 5,709 | 5,891 |
| Net loss | $(10,481) | $(9,964) | $(34,342) | $(29,079) |
| Net loss per share - basic and diluted | $(0.08) | $(0.08) | $(0.25) | $(0.23) |
| Basic and diluted weighted average shares outstanding | 137,589 | 127,424 | 137,263 | 126,837 |
| Other comprehensive loss: | ||||
| Net loss | $(10,481) | $(9,964) | $(34,342) | $(29,079) |
| Unrealized gain (loss) on marketable securities | 577 | 77 | 449 | (128) |
| Comprehensive loss | $(9,904) | $(9,887) | $(33,893) | $(29,207) |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.Compass Therapeutics, Inc. and Subsidiaries
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.